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Abstract
Background: Aberrant TGF-β1 signaling is suggested to be involved in gastric carcinogenesis. However, the role of
TGF-β1 in intestinal-type [i-GC] and diffuse-type [d-GC] gastric cancer remains largely unknown. In this study,
we evaluated the expression of TGF-β1 signaling molecules and compared the clinicopathological features of
i-GC and d-GC.
Methods: Patients (n=365, consecutive) who underwent curative gastrectomy for gastric adenocarcinoma in 2005
were enrolled. We performed immunohistochemical staining of TGF-β1, TGF-β1 receptor-2 (TβR2), Smad4, p-ERK1/2,
TGF-activated kinase (TAK)1, and p-Akt in 68 paraffin-embedded tumor blocks (33 i-GC and 35 d-GC), scored the
expression according to the extent of staining, and evaluated differences between the histologic subtypes.
Results: Patients with d-GC differed from those with i-GC as follows: younger and more likely to be female; more
aggressive stage; higher recurrence rate. The expression of TGF-β1 and TβR2 was higher in i-GC (P = 0.05 and P <0.001,
respectively). The expression of Smad4, a representative molecule of the Smad-dependent pathway, was decreased in
both subtypes. TAK1 and p-Akt, two major molecules involved in the Smad-independent pathway, were over-expressed
(69 ~ 87 % of cases stained), without a statistically significant difference between i-GC and d-GC. Of note, the
expression of p-ERK1/2, a Smad-independent pathway, was significantly increased in i-GC (P = 0.008).
Conclusions: The clinicopathological characteristics vary in different histologic gastric cancer subtypes. Although
TGF-β1 signaling in gastric cancer cells appears hyper-activated in i-GC compared to d-GC, the Smad-dependent
pathway seems down-regulated while the Smad-independent pathway seems up-regulated in both histologic subtypes.
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Background
In 2012, gastric cancer was responsible for 723,000
deaths and was ranked as the world’s third leading cause
of cancer mortality [1]. Gastric cancer was also the sec-
ond most common malignancy in Korea [2]. Although
conventional chemotherapy has improved the overall
prognosis of gastric cancer, the survival rate of patients
with advanced cancer still falls short of expectations.
With the recent advances in our understanding of the
molecular basis of this deadly disease, deregulated
cellular pathways were identified and targeted, providing
new therapeutic options beyond conventional chemo-
therapies. Indeed, human epidermal growth factor recep-
tor 2 (HER2) and vascular endothelial growth factor
receptor 2 (VEGFR2) have been evaluated as therapeutic
targets and are now available as treatment targets in
metastatic gastric cancer [3, 4].
Data from one multicenter transcriptome study [5]
and The Cancer Genome Atlas [6] established the sig-
nificance of transforming growth factor beta 1 (TGF)-β1
signaling on gastric cancer progression, supporting its
role as an emerging candidate biomarker for gastric can-
cer. In line with these pivotal studies, others also showed
the relation between high expression of TGF-β1 and un-
favorable prognosis of gastric cancer patients [7–10].
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TGF-β1 has an important role not only in normal
physiologic functions like embryonic development,
angiogenesis, fibrosis, and wound healing, but also in
cancer development and progression. Furthermore,
TGF-β1 has a dual role in cancer, as a tumor suppressor
in earlier stages and tumor promoter in later stages [11].
TGF-β1 signaling falls into either the canonical Smad-
dependent pathway or non-canonical Smad-independent
pathway. The Smad-independent pathway includes the
phosphoinositol-3 kinase (PI3K), mitogen-activated pro-
tein kinase (MAPK), and small guanosine triphosphatase
(GTPase) pathways. These pathways are most often im-
plicated in tumor cell motility and migration [12].
Gastric cancer is characterized by tumor heterogeneity.
The Lauren classification is a well-known histologic classi-
fication system used in gastric cancer [13]. According to
the Lauren classification, gastric cancer is categorized into
intestinal (i-GC), diffuse (d-GC), or mixed types. Typic-
ally, i-GC tumors form gastric gland-like structures, while
d-GCs do not. In addition to morphologic differences,
these two types are known to have different epidemiologic,
clinical, and molecular manifestations as well [14].
Our study aimed to investigate the expression pattern
of TGF-β1 pathway-related molecules, including Smad-
dependent and Smad-independent factors, in gastric
cancers of different Lauren’s classifications.
Methods
Patients and samples
A series of 774 gastric cancer patients, who have under-
gone curative gastrectomy at Yonsei University Medical
University Hospital (Seoul, Korea) from May 2005 to
December 2005, were enrolled in this study. Patients
who had a history of concurrent tumor, neoadjuvant
chemotherapy or radiotherapy, preoperatively or intra-
operatively detected metastasis, unavailable Lauren’s
data, and follow-up loss were excluded from this study.
The clinicopathologic data of the remaining 365 patients
who satisfied the inclusion criteria were analyzed to in-
vestigate the clinicopathological differences between i-
GC and d-GC. Patients were followed up clinically for at
least 5 years after surgery, except in mortality cases. The
follow-up time ranged from 3 to 69 months, with an
average follow-up time of 55 months. We performed an
analysis of mRNA microarray in the cases of 158 tissues
among 365 cases as a pilot study. We observed that in-
creased expression of TGF- β pathway gene modules
were associated with unfavorable survival from that ana-
lysis (data not shown). Based on the results, further ex-
periment of immunohistochemical study were planned
to validate the clinical meaning of TGF- β signaling in
gastric cancer subtypes. For more precise analysis, we
decided to match the cases with considering the under-
lying clinic-pathological characteristics between the two
subtypes of gastric cancer which might affect the inter-
pretation of our results. A total of 68 tissues among 158
cases, therefore, were selected after some cases were
dropped out because of the problems of tissue availabil-
ity and readability. Written informed consent was ob-
tained from all patients and the study was approved by
the Institutional Review Board of Severance Hospital,
Yonsei University (4-2012-0427).
Immunohistochemistry
Paraffin-embedded sections (4 μm thick) were de-
paraffinized with xylene and rehydrated in decreasing con-
centrations of ethanol. Sections were then incubated with
3 % H2O2 for 30 min at room temperature. The slides
were immersed in 0.01 M citrate buffer (pH 6.0) for
10 min for antigen retrieval and then immersed in
phosphate-buffered saline (PBS) containing 15 % goat
serum. The primary antibodies were rabbit anti-human
TGF-β1 polyclonal antibody (1:100; Santa Cruz, USA),
mouse anti-human Smad4 monoclonal antibody (1:100;
Santa Cruz, USA), mouse anti-human TGF-β receptor II
(TβRII) monoclonal antibody (1:100; Santa Cruz, USA),
rabbit anti-human phosphorylated (p)-Akt monoclonal
antibody (1:100; Abcam, UK), rabbit anti-human p-
extracellular signal-regulated kinase (ERK)1/2 polyclonal
antibody (1:100; Santa Cruz, USA) and rabbit anti-human
TGF-activated kinase 1 (TAK1) polyclonal antibody
(1:100; Abcam, UK). After rinsing with PBS, secondary
antibodies were added (goat anti-rabbit polymerized horse
radish peroxidase [HRP]-labeled secondary antibody or
goat anti-mouse IgG secondary antibody; Envision kit,
DAKO, Denmark), and the slides placed in a thermostatic
water bath at 37 °C for 30 min. After rinsing with PBS, the
samples were counterstained using hematoxylin.
Evaluation of results of immunohistochemical staining
Tissue samples were scored independently by two re-
searchers (H.K. and K.H.P), who were blinded to the
clinical data. Staining results for TGF-β1, TβR2, Smad4,
TAK1, p-ERK1/2, and p-Akt were classified by estimat-
ing the percentage of epithelial cells exhibiting specific
immunoreactivity: negative (no immunoreactivity); weak
(0 to 33 % positive cells); moderate (33 to 67 % positive
cells); and strong (>67 % positive cells) (Fig. 1). Only
samples exhibiting moderate and strong immunoreactiv-
ity were considered positive. We used following cells as
internal positive controls: inflammatory cells for TGF-β1
and p-Erk1/2; endothelial cells for TβR2 and Smad4;
Myocytes for p-Akt1. For TAK1, it was difficult to find
internal positive control (Additional file 1: Figure S1).
Statistical analysis
Statistical analyses were performed using the SPSS stat-
istical software program for Windows version 21 (SPSS
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Inc., Chicago, IL, USA). The association between vari-
ables was tested using Pearson’s χ2or Fisher’s exact tests
for categorical variables. The survival data were analyzed
using the Kaplan-Meier method and the log-rank test
was used for assessing differences between groups. Two-
sided values of P <0.05 were considered to indicate sta-
tistically significant differences.
Results
Differences in clinicopathologic features according to
Lauren’s classification
The clinicopathologic data for patient groups sorted
based on Lauren’s classification are summarized in Ta-
bles 1 and 2. Patients with d-GC were significantly youn-
ger (P <0.001) and more likely to be female (P <0.001).
A larger proportion of the d-GC patients underwent total
gastrectomy with more upper tumor location (P = 0.001)
than i-GC patients. Patients with d-GC also had an in-
creased propensity for recurrent disease (P = 0.028), in
particular, peritoneal recurrence (P = 0.008). The overall
survival rate of d-GC patients showed an unfavorable
trend compared to that of i-GC patients (P = 0.072).
Tumors in patients with d-GC were larger (P =
0.021), more undifferentiated (P <0.001), and of
higher T- (P <0.001) and N-stages (P = 0.004) than
those in i-GC patients. Lymphovascular invasion
(LVI) was not different between the two patient
groups (P = 0.099).
After selecting stage matched gastric cancer patients
according to Lauren’s classification (Table 3), none of
Fig. 1 Immunohistochemical staining of TGF-β1 signaling molecules. TGFβR2, TGF receptor II; TAK1, TGF associated kinase 1; i-GC, intestinal type
gastric cancer; d-GC, diffuse type gastric cancer. All cases were positively stained with each TGF-β1 signaling molecules. TGF-β1, TβR2 and TAK1
were stained in cell membrane and cytoplasm, while Smad4, p-Erk1/2 and p-Akt were stained in nucleus
Table 1 Differences in demographic features of gastric cancer patients according to Lauren’s classification
Intestinal-type Diffuse-type P-value
(n = 204) (n = 161)
Age <60 years 86 113 <0.001*
>60 years 118 47
Sex Male 163 99 <0.001*
Female 41 62
Extent of resection TG 30 47 0.001*
STG 174 114
Location Fundus 16 48 0.001*
Body 67 79
Antrum 117 63
Recurrence (−) 172 122 0.028*
(+) 32 39




Survival Alive 175 126 0.072
Dead 29 35
*P <0.05, calculated using; N.S. not significant, TG total gastrectomy, STG subtotal gastrectomy
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the parameters between i-GC and d-GC patients showed
statistically significant differences, with the exception of
patient age (younger in d-GC; P <0.01).
Expression of TGF-β1 signaling molecules
Positive expression rate of TGF-β1 signaling molecules
in i-GC and d-GC, respectively, was as follows; TGF-β1
(61 and 34 %), TβR2 (100 and 66 %), Smad4 (26 and
27 %), p-ERK1/2 (82 and 37 %), p-Akt (72 and 69 %),
and TAK1 (87 and 83 %) (Fig. 1; Expression data is sum-
marized in Table 4).
TGF-β1 and TβR2 were activated in both gastric can-
cer histologic subtypes. However, all the TGF-β1 signal-
ing pathway molecules were expressed at higher levels in
i-GC than in d-GC tumors (P = 0.05, P < 0.001 in all).
The co-expression rate of TGF-β ligand and receptor
was much higher in i-GC (20/33, 64.5 %) than in d-GC
tumors (11/37, 35.5 %; P = 0.015). The expression of
Smad4, a representative molecule of the Smad-dependent
pathway, was decreased in both subtypes, albeit without
statistically significant difference between the subtypes
Table 2 Differences in pathological characteristics according to Lauren’s classification
Intestinal-type Diffuse-type P-value
(n = 204) (n = 161)
Size <30 mm 134 88 0.021*
>30 mm 70 73
Differentiation Differentiated 188 4 <0.001*
Poorly differentiated 16 157
LVI (−) 140 97 0.099
(+) 64 64








*P <0.05, calculated using; N.S. not significant, LVI lymphovascular invasion
Table 3 Clinicopathologic characteristics of 68 randomly
selected gastric cancer patients whose tumors were utilized for
immunohistochemical analysis
Intestinal-type Diffuse-type P-value
(n = 33) (n = 35)
Age <60 years 10 25 <0.01
>60 years 23 10
Sex Male 24 25 NS
Female 9 10
Depth of invasion T1 9 10 NS
≥T2 24 25
LN metastasis Negative 17 20 NS
Positive 16 15
TNM stage* I 8 11 NS
II 14 16
III 11 8
* 7th ed., N.S. not significant
Table 4 Expression of TGF-β signaling molecules according to
Lauren’s classification
Intestinal-type Diffuse-type P-
value(n = 33) (n = 35)
TGF-β1 Low 13 23 0.050
High 20 (61 %) 12 (34 %)
TβR2 Low 0 12 <0.001
High 33 (100 %) 23 (66 %)
Smad4 Low 23 25 0.588
High 8 (26 %) 9 (27 %)
p-ERK1/2 Low 3 12 0.008
High 14 (82 %) 7 (37 %)
p-Akt Low 9 11 0.796
High 23 (72 %) 24 (69 %)
TAK1 Low 4 6 0.758
High 27 (87 %) 29 (84 %)
TGF-β1 transforming growth factor-β1, T βR2 TGF-β receptor 2, p-ERK phos-
phorylated extracellular signal-regulated kinase, TAK1 TGF-activated kinase1
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(P = 0.588). Among factors involved in the Smad-
independent pathway, p-Akt and TAK1 were over-
expressed, without a statistically significant difference
between i-GC and d-GC (P = 0.796 and P = 0.742, re-
spectively). Of note, the expression of p-ERK1/2 was
higher in i-GC than in d-GC (P = 0.008).
Further, the increased TGF-β1 signaling pathway was
significantly correlated with poor overall survival in gas-
tric cancer patients (50.2 ± 5.2 months vs. 63.8 ±
1.8 months, P = 0.03) (Fig. 2).
Discussion
In this study, we identified significant clinicopathologic
differences between i-GC and d-GC. Our study could sup-
port the possibility of the conversion of TGF- β1 signaling
from a Smad-dependent to a Smad-independent pathway
in case of malignant status, a hypothesis suggested in one
previous study [15]. In addition, we propose that gastric
cancer subtypes may utilize a different Smad-independent
signaling pathway. Our data suggest that i-GC might de-
pend more on the p-ERK1/2 pathway than d-GC. It can
be supported by the previous study [16] which reported
that p-ERK1/2 pathway is associated with H. pylori infec-
tion- well known proven cause of i-GC [17].
TGF-β1 has the potential to function as a tumor sup-
pressor (via its effects on proliferation, replication
potential, and apoptosis), or as a tumor promoter (via its
effects on migration, invasion, angiogenesis, and the im-
mune system) [11]. Based on animal models and in vitro
studies, Elliot and Blobe [18] proposed a hypothesis, in
which during early tumorigenesis, TGF-β1-mediated
tumor suppressor activity functions through a Smad-
dependent pathway, while tumor promoter activity
acts through a Smad-independent pathway. However,
no complete clinical study included empirical data
supporting this hypothesis, except that of Kim et al.
[15]. Their analysis of a 332-tissue microarray, which
was performed along the normal epithelium-atrophic
gastritis-dysplasia-carcinoma sequence, showed that
TGF-β1 and TβR1 expression continually increased
along this sequence, while Smad 2/3 and Smad4 de-
creased as carcinoma progressed. Their study, how-
ever, was limited because they did not evaluate the
expression of Smad-independent signaling molecules.
In our present study, we evaluated two TGF-β1 path-
ways in gastric cancers by assessing the expression of
Smad -dependent and Smad -independent signaling
molecules, although we did not compare the expres-
sion of TGF-β1 signaling molecules between tumor
and normal tissue. When considering our data and
the study of Kim et al. [15], we suggest a model for
the role of TGF-β in gastric carcinogenesis, whereby
Fig. 2 Kaplan-Meier analysis of overall survival between high TGF-β1 signal and low TGF-β1 signal. Patients group with high TGF-β1 showed
poorer overall survival (50.2 ± 5.2 months vs. 63.8 ± 1.8 months, p = 0.03)
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TGF-β1 signaling changes from the tumor-suppressive
Smad-dependent pathway to a tumor-activating Smad-
independent pathway as the cancer progresses, irre-
spective of histologic subtypes of gastric cancer.
The main sources of TGF-β1 are stromal cells, such as
fibroblasts, lymphocytes, and macrophages [12]. There-
fore, the expression of TGF-β1 within tumors is higher
in d-GC than in i-GC, largely because d-GC has more
stromal components [5]. However, our study, in which
we assessed the immunoreactivity of only cancer cells
not stroma, revealed another interesting aspect of TGF-
β signaling in gastric cancer; the expression of ligand
and receptor of TGF-β1 signaling was increased in gas-
tric cancer tissue, which suggests a potential autocrine
loop in gastric cancer. Interestingly, in our data, co-
expression of both ligand and receptor was higher in i-
GC than in d-GC. It is thus conceivable that a paracrine
effect of TGF-β1 signaling is dominant in d-GC, in
which cancerous stromal cells are abundant, while an
autocrine function of TGF-β1 might play an important
role in i-GC. We will address this hypothesis in our fu-
ture studies.
We note the limitations of our current study; our
sample of gastric cancer tissues was relatively small
and had a possibility of selection bias. In addition, we
did not compare the expression of TGF-β1 signaling
molecules in cancer tissues with that in matched nor-
mal tissues.
Therapeutic strategies targeting TGF-β1 signaling in
cancer treatment is a burgeoning field of research [19].
The current results can augment our understanding of
the role of TGF-β1 signaling in distinct histologic sub-
types of gastric cancer.
Conclusions
The clinicopathological characteristics vary in different
histologic gastric cancer subtypes. Although TGF-β1 sig-
naling in gastric cancer cells appears hyper-activated in
i-GC compared to d-GC, the Smad-dependent pathway
seems down-regulated while the Smad-independent
pathway seems up-regulated in both histologic subtypes.
Of note, the expression of p-ERK1/2, a Smad-
independent pathway factor, was significantly increased
in i-GC.
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